Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Topic in appraisal
Process STA Standard
ID number 6325

Provisional Schedule

Expected publication 05 November 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Stakeholders

Companies sponsors Gilead Sciences Ltd (brexucabtagene autoleucel)
Others Department of Health and Social Care
  NHS England
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Baxter Healthcare (cyclophosphamide, doxorubicin)- No CAU- Not participating
  BeiGene UK (zanubrutinib)- CAU signed- Participating
  Celltrion Healthcare UK (rituximab)- No CAU- Not participating
  Dr Reddy’s Laboratories UK (bendamustine)- No CAU- Not participating
  Hospira UK (cytarabine, vincristine)- No CAU- Not participating
  Jazz Pharmaceuticals UK (cytarabine)- No CAU- Not participating
  Medac GmbH (doxorubicin)- No CAU- Not participating
  Pfizer (rituximab, doxorubicin)- No CAU- Not participating
  Roche (rituximab)- No CAU- Not participating
  Sandoz (rituximab, cyclophosphamide)- No CAU- Not participating
  Seacross Pharmaceuticals (bendamustine, doxorubicin)- No CAU- Not participating
  Zentiva (bendamustine)- No CAU- Not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Cell and Gene Therapy Catapult
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 July 2025 Committee meeting: 1
06 December 2024 Invitation to participate
30 September 2024 - 28 October 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
16 May 2024 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual